Login/Sign Up
MRP ₹2009.21
(Inclusive of all Taxes)
₹301.4 Cashback (15%)
Provide Delivery Location
About Gefticip 250 mg Tablet
Gefticip 250 mg Tablet belongs to the group of medicine called ‘anti-cancer’, primarily indicated in lung cancer treatment. Lung cancer is the uncontrolled growth of abnormal cells in one or both lungs. These abnormal cells do not carry out normal lung cell functions and do not develop into healthy lung tissue. In this disease, cells of the lung grow uncontrollably, and if not detected at an early stage may spread to other body parts, including the brain.
Gefticip 250 mg Tablet contains 'Gefitinib' which belongs to the group of medicines known as 'kinase inhibitors'. It works by stopping the action of an abnormal protein that causes the multiplication of cancerous cells. In this way, it stops the spread of cancerous cells.
Take Gefticip 250 mg Tablet as prescribed by your doctor. You are suggested to take Gefticip 250 mg Tablet as long as your doctor has prescribed it after checking your medical condition. In some cases, you may experience certain common side effects such as itching or skin rash, acne, nail problems, vomiting, diarrhea, and loss of appetite. Most of these side effects do not require medical attention and will resolve gradually over time. However, you are advised to talk to your doctor if you experience these side effects persistently.
To treat your condition effectually, continue taking Gefticip 250 mg Tablet for as long as your doctor has prescribed. Do not take Gefticip 250 mg Tablet if you are pregnant or planning for pregnancy as Gefticip 250 mg Tablet causes serious birth defects. Gefticip 250 mg Tablet should not be taken by breastfeeding mothers as it passes into breast milk and may cause a possible risk to the infant. Elderly people are more sensitive to medicine so they may adjust the dosage according to their condition. Avoid consuming alcohol along with Gefticip 250 mg Tablet as it could lead to increased dizziness.
Uses of Gefticip 250 mg Tablet
Have a query?
Directions for Use
Medicinal Benefits
Gefticip 250 mg Tablet is indicated to the patients dealing with non-small cell lung cancer. Cancer of this type tends to spread quickly in other parts of the body. Gefticip 250 mg Tablet travels through the bloodstream and effectively destroys cancerous cells of the lung and other parts of the body. Gefticip 250 mg Tablet is a ' tyrosine kinase inhibitor (TKI)', that stops the uncontrolled growth and spread of cancerous cells. It acts by stopping the abnormal protein action that is responsible for the multiplication of cancerous cells. Whenever a new healthy cell is formed, it undergoes a usual process of maturity. Cancerous cells form new cells more quickly, so Gefticip 250 mg Tablet targets cancerous cells and blocks the action of Tyrosine kinase enzymes (responsible for causing cancer). It also decreases the blood supply to cancer tumors to slow down the growth of the tumor. In this way, Gefticip 250 mg Tablet stops the production, spread and growth of cancerous cells in the body.
How Gefticip 250 mg Tablet Works
Storage
What if I have taken an overdose of Gefticip 250 mg Tablet
Drug Warnings
Tell your doctor if you have liver or kidney disease, vision problems, breathing problems or taking any blood thinner like warfarin. Before undergoing any surgery, it is advised to tell the medical professional who performs the procedure about all the medicines you are taking. Some persons may experience diarrhoea as a side effect of Gefticip 250 mg Tablet , so it is advised to drink a lot of water and tell your doctor in such a case. Inform your doctor if you notice any severe side effects of Gefticip 250 mg Tablet , including shortness of breath, worsening cough, and other vision problems. You need to go to regular blood tests to check if this medicine is working fine for you. Avoid high-fibre foods, raw fruits, cereals, vegetables, and drink lots of water as Gefticip 250 mg Tablet may cause diarrhoea.
Drug-Drug Interactions
Login/Sign Up
Drug-Food Interactions
Login/Sign Up
Diet & Lifestyle Advise
Habit Forming
Therapeutic Class
Alcohol
Unsafe
You are recommended to avoid alcohol consumption with Gefticip 250 mg Tablet as it may increase the risk of side effects such as dizziness, drowsiness, or difficulty in concentrating.
Pregnancy
Unsafe
Gefticip 250 mg Tablet is restricted to use in pregnancy. A woman needs to have a negative pregnancy test before starting treatment with this medicine. It is better to use effective birth control methods to prevent pregnancy while taking this medicine or at least 6 months after taking the last dose of Gefticip 250 mg Tablet .
Breast Feeding
Unsafe
Gefticip 250 mg Tablet should not be taken by breastfeeding mothers as it passes into breast milk and may cause a possible risk to the infant.
Driving
Caution
It is not known if Gefticip 250 mg Tablet may affect your driving ability or not. Drive only if you are physically stable and mentally focussed. If you experience drowsiness after taking this medication, you should not drive or operate any machinery or vehicles.
Liver
Caution
Gefticip 250 mg Tablet should be taken with caution in patients dealing with liver disease. The doctor may adjust the dose according to the medical condition of the patient.
Kidney
Caution
Gefticip 250 mg Tablet is safe to take by patients dealing with kidney disease as prescribed by their doctor. The doctor may adjust the dose according to the medical condition of the patient.
Children
Unsafe
Gefticip 250 mg Tablet is not recommended for children below 18 years as the safety and effectiveness were not established.
Gefticip 250 mg Tablet is used to treat non-small cell lung cancer.
Gefticip 250 mg Tablet works by stopping the action of an abnormal protein that causes the multiplication of cancerous cells. Thereby, it prevents the spread of cancerous cells.
The most common sign of lung cancer is a cough that lasts long and gets worse with time. Sometimes, a patient may notice blood in the cough. Chest pain is also a sign of lung cancer followed by coughing.
It is suggested to avoid taking an antacid or stomach acid-reducing medicine within 6 hours after taking Gefticip 250 mg Tablet as it may make the medicine less effective if taken simultaneously.
Gefticip 250 mg Tablet is safe to be taken by a diabetic person. However, take Gefticip 250 mg Tablet only after asking a doctor as they may adjust the dosing according to the patient's condition.
Country of origin
Manufacturer/Marketer address
We provide you with authentic, trustworthy and relevant information
Buy best Neoplastic Disorders products by
Intas Pharmaceuticals Ltd
Dr Reddy's Laboratories Ltd
Natco Pharma Ltd
Celon Laboratories Pvt Ltd
Cipla Ltd
Sun Pharmaceutical Industries Ltd
BDR Pharmaceuticals Internationals Pvt Ltd
Adley Formulations
Admac Lifesciences(Oncology)
Alkem Laboratories Ltd
Neon Laboratories Ltd
Glenmark Pharmaceuticals Ltd
United Biotech Pvt Ltd
Halsted Pharma Pvt Ltd
Emcure Pharmaceuticals Ltd
Zydus Healthcare Ltd
Zydus Cadila
Samarth Life Sciences Pvt Ltd
Mylan Pharmaceuticals Pvt Ltd
Hetero Drugs Ltd
GLS Pharma Ltd
Axiommax Oncology Pvt Ltd
Fresenius Kabi India Pvt Ltd
Hetero Healthcare Pvt Ltd
Torrent Pharmaceuticals Ltd
Pfizer Ltd
Getwell Life Sciences India Pvt Ltd
Khandelwal Laboratories Pvt Ltd
Lupin Ltd
Adley Pharmaceuticals Ltd
Cadila Healthcare Ltd
Aureate Healthcare
Novartis India Ltd
Therdose Pharma Pvt Ltd
RPG Life Sciences Ltd
Abbott India Ltd
Biochem Pharmaceutical Industries Ltd
Delarc Pharmaceuticals Pvt Ltd
Aimcad Biotech Pvt Ltd
Reliance Formulation Pvt Ltd
Shilpa Medicare Ltd
Wembrace Biopharma Pvt Ltd
Zee Laboratories Ltd
Msn Laboratories Pvt Ltd
Amps Biotech Biotech Pvt Ltd
Astra Zeneca Pharma India Ltd
Getwell Oncology Pvt Ltd
Caitlin Oncology
Medaegis Biotek Pvt Ltd
Dabur India Ltd
Del Trade International Pvt Ltd
MEDICAMEN BIOTECH LTD
Medion Biotech Pvt Ltd
Oncostar Pharma Pvt Ltd
Panacea Biotec Ltd
Sarabhai Chemicals (India) Pvt Ltd
Bhardwaj India Pvt Ltd
Getwell Pharmaceutical Pvt Ltd
Cytogen
Lucien Life Sciences
Symbion Lifescience
Bangalore Pharmaceutical and Research Laboratory Pvt Ltd (BPRL)
Cadila Pharmaceuticals Ltd
Miracalus Pharma Pvt Ltd
Vhb Life Sciences Inc
Allieva Pharma Pvt Ltd
Amneal Healthcare Pvt Ltd
Ipca Laboratories Ltd
Zuvius Lifesciences Pvt Ltd
Eli Lilly and Company (India) Pvt Ltd
Eris Life Sciences Ltd
Johnson & Johnson Pvt Ltd
Maximal Healthcare Pvt Ltd
Admac Pharma Ltd
Akumentis Healthcare Ltd
Biocon Ltd
Bruck Pharma Pvt Ltd
Caitlin Biotech Pvt Ltd
Ferring Pharmaceuticals Pvt Ltd
Fresenius Kabi Oncology Ltd
Hilfen Pharmaceuticals Pvt Ltd
Medicamen Biotech Ltd
Sayre Therapeutics Pvt Ltd
Zuventus Healthcare Ltd
Boehringer Ingelheim India Pvt Ltd
Selway Lifesciences Pvt Ltd
Trikem Remedies Llp
Adley Oncology
Corona Remedies Pvt Ltd
Eisai Pharmaceuticals India Pvt Ltd
GlaxoSmithKline Pharmaceuticals Ltd
Gynofem Healthcare Pvt Ltd
Hillrock Biotech Pvt Ltd
Janssen Pharmaceuticals Pvt Ltd
Jodas Expoim Pvt Ltd
Mankind Pharma Pvt Ltd
Merck Ltd
Oncobiotek Drugs Pvt Ltd
Pharm Products Pvt Ltd
Rhone Poulenc Rorer India Pvt Ltd